← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Phoenicia Biosciences, Inc.
Weston, MA
$9,123,998
Total funding
9
Grants
Funding over time
peak $1.8M · FY2009–22$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$9,123,998 · 9
By mechanism
R33$5,206,823 · 1
R41$1,636,697 · 5
R42$999,992 · 1
R44$991,591 · 1
R43$288,895 · 1
Investigators at Phoenicia Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of a Clinical Hemoglobin Modulator$1,843,809
R33 · FY2021 · HL
Development of a Clinical Hemoglobin Modulator$1,733,012
R33 · FY2020 · HL
Development of a Clinical Hemoglobin Modulator$1,630,002
R33 · FY2022 · HL
Virus-targeted therapeutic for EBV-Associated Malignancies$519,583
R44 · FY2017 · CA
Development of a clinical hemoglobin modulator$499,996
R42 · FY2014 · HL
Development of a clinical hemoglobin modulator$499,996
R42 · FY2015 · HL
Next Generation Therapeutics for Hemoglobinopathies$491,254
R41 · FY2012 · HL
Virus-targeted therapeutic for EBV-Associated Malignancies$472,008
R44 · FY2016 · CA
Oral Agents to Stimulate Neutrophil Production$350,566
R41 · FY2010 · HL
in vivo Studies of Clinical Stage Globin Modulators$304,344
R41 · FY2011 · HL
Virus-Targeted Therapy for Malignancies$288,895
R43 · FY2011 · CA
Development of an Oncogene-Targeted Therapeutic$271,227
R41 · FY2009 · CA
Topical Therapeutic to Promote Healing of Chronic Wounds$219,306
R41 · FY2013 · GM